Menu Search
Equities

Shin Nippon Biomedical Laboratories Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
YB3:FRA

Shin Nippon Biomedical Laboratories Ltd

Actions
  • Price (EUR)9.05
  • Today's Change-0.25 / -2.69%
  • Shares traded1.00
  • 1 Year change-9.50%
  • Beta-0.2914
Data delayed at least 15 minutes, as of Feb 16 2026 07:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shin Nippon Biomedical Laboratories Ltd is a Japan-based company engaged in contract research organization (CRO) business, translational research (TR) business, and other businesses. It operates through four business segments. CRO segment includes non-clinical business using laboratory animals, cells, and bacteria to confirm the efficacy and safety of drugs under development by pharmaceutical companies, and clinical business, conducting trials to confirm efficacy and safety in humans. Translational Research segment develops nasal delivery platform technologies and conducts non-clinical and clinical testing necessary for the evaluation and approval of pharmaceuticals and others. Medipolis segment operates accommodation facilities and geothermal power generation businesses. United States Real Estate segment rents out multi-purpose industrial buildings constructed on sites owned by its subsidiary. It also undertakes administrative work and provides support for the group's operations.

  • Revenue in JPY (TTM)31.37bn
  • Net income in JPY3.99bn
  • Incorporated1973
  • Employees1.44k
  • Location
    Shin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
  • Phone+81 355655001
  • Fax+81 355656160
  • Websitehttps://snbl.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.